Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

Clinical trial NCT06839053 · RECRUITING

Trial details

NCT number: NCT06839053
Sponsor: Fred Hutchinson Cancer Center
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Lymphocytic Leukemia Mantle Cell Lymphoma Recurrent Chronic Lymphocytic Leukemia Recurrent Mantle Cell Lymphoma Recurrent Small Lymphocytic Lymphoma Refractory Chronic Lymphocytic Leukemia Refractory Mantle Cell Lymphoma Refractory Small Lymphocytic Lymphoma Small Lymphocytic Lymphoma

Start date: 2025-06-02
Primary completion: 2028-08-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.